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Objective: Numerous studies have suggested that microRNA-126 (miR-126) is involved in development of various
cancer types as well as in malignant proliferation and invasion. However, its role in human prostate cancer (PCa) is
still unclear. The aim of this study was to investigate miR-126 expression in PCa and its prognostic value for PCa
patients undergoing radical prostatectomy.
Methods: A series of 128 cases with PCa were evaluated for the expression levels of miR-126 by quantitative
reverse-transcription PCR (qRT-PCR). Kaplan-Meier analysis and Cox proportional hazards regression models were
used to investigate the correlation between miR-126 expression and prognosis of PCa patients.
Results: Compared with non-cancerous prostate tissues, the expression level of miR-126 was significantly decreased
in PCa tissues (PCa vs. non-cancerous prostate: 1.05 ± 0.63 vs. 2.92 ± 0.98, P < 0.001). Additionally, the loss of miR-126
expression was dramatically associated with aggressive clinical pathological features, including advanced
pathological stage (P = 0.001), positive lymph node metastasis (P = 0.006), high preoperative PSA (P = 0.003) and
positive angiolymphatic invasion (P = 0.001). Moreover, Kaplan–Meier survival analysis showed that PCa patients with
low miR-126 expression have shorter biochemical recurrence (BCR)-free survival than those with high miR-126
expression. Furthermore, multivariate analysis indicated that miR-126 expression was an independent prognostic
factor for BCR-free survival after radical prostatectomy.
Conclusion: These findings suggest for the first time that the loss of miR-126 expression may play a positive role in
the malignant progression of PCa. More importantly, the downregulation of miR-126 may serve as an independent
predictor of BCR-free survival in patients with PCa.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1740080792113255.
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Prostate cancer (PCa) represents one of the most preva-
lent malignancies among men worldwide and the second
most frequent cause of male cancer-related death in most
Western countries [1]. PCa is a clinically heterogeneous-
multifocal and highly aggressive disease [2]. Even when* Correspondence: waike@sohu.com
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stated.the tumor is apparently confined to prostate, it encom-
passes a broad spectrum of diseases, some of which are
characterized by extremely indolent behavior and others
by very poor outcome [3]. Despite the advancement of
therapeutic strategies, there are few effective therapeutic
options for advanced PCa. The annual morbidity rate of
this cancer has increased by 14% since 1990 [4]. It is the
most troublesome aspect that how to diagnose PCa patients
at early stage. Several clinicopathological features, including
tumor volume, pathological grade, status of lymph node. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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used for diagnosis and prognosis [5,6]. However, there is no
widely accepted method for quantifying tumor volume [7];
pathological grade scoring methods can result in significant
inter-observer variations, particularly when defining inter-
mediate tumor grades [8]; accumulating studies have found
that PCa patients with the equivalent PSA level could have
various clinical outcomes because of the molecularly het-
erogeneous subtypes [9]. In order to overcome these limita-
tions, efficient diagnostic and prognostic biomarkers for
PCa are extremely necessary for the early detection of ag-
gressive PCa and for the improvement of clinical outcome
of patients with this disease.
MicroRNAs (miRNAs), which are small non-coding
RNA molecules with 19–24 nucleotides in length, play
crucial roles in the regulation of basic biological processes,
including cell growth, apoptosis and differentiation, by
silencing specific target genes through impairing their
translation or both specifically binding to the 3′-untrans-
lated regions (3′UTR) of target mRNAs [10]. Until now,
there have been more than 1,400 human miRNA se-
quences identified and many of them have been demon-
strated to be implicated into cancer pathogenesis [11].
Functionally, miRNAs can act either as oncogenes or
tumor suppressors according to the roles of their target
genes. With regard to the relationship between cancer and
miRNAs, accumulating studies have detected the specific
miRNA profiles in various solid tumors and several miRNA
signatures have been identified as diagnostic markers or
therapeutic targets. Especially in PCa, Walter et al. [12] per-
formed a comprehensive differential miRNA expression
analysis of a group of PCa patients with different Gleason
score compared to their corresponding normal epithelium
and stromal tissue. Mavridis et al. [13] comprehensively
profiled the expression of the mature miRNA-224 molecule
in benign prostatic hyperplasia and PCa with a reliable and
cost-efficient method based on quantitative real-time PCR.
They also indicated that miR-224 may be downregulated in
PCa, that miR-244 expression may be gradually decreased
as malignancy progresses, and that miR-224 expression
may be associated with favorable prognosis. These findings
suggest that miRNAs have a relevant role as biomarkers
in PCa, and it is of great significance to screen miRNA
markers with diagnostic and prognostic values for patients
with PCa.
MicroRNA-126 (miR-126) originates from a common
precursor structure located within intron 7 of epidermal
growth factor-like domain 7 (EGFL7) [14]. It is highly
expressed in vascular endothelial cells and functions as a
key positive regulator to promote angiogenesis in response
to angiogenic growth factors by repressing negative regula-
tors of signal transduction pathways [15]. Recent studies
have found the involvement of miR-126 in various human
malignancies. For example, miR-126 may be downregulatedin non-small cell lung tumor tissues, and may correlate
with microvessel density and clinical outcomes [16]; the de-
creased expression of miR-126 may be associated with poor
metastasis-free survival of breast cancer patients [17]; Loss
of miR-126 may be more frequent in colorectal cancers
with metastasis [18]. In contrast, miR-126 may be act as
oncogene since it has been demonstrated to be a significant
negative prognostic factor for squamous cell carcinomas
[19]. These contradictory results may indicate that the roles
of miR-126 in various tissues may be different because of
its high tissue specificity. Notably, Saito et al. [20] in 2009
showed that miR-126 was downregulated in PCa cell lines.
Walter et al. [12] in 2013 by PCR array profiling identified
miR-126 as one of the downregulation miRNAs in high
grade PCa. However, little is known about the expression of
miR-126 in human PCa tissues, and data on its potential
prognostic value in PCa are completely lacking.
In the current study, a series of 128 cases with PCa
were evaluated for the expression levels of miR-126 by
quantitative reverse-transcription PCR (qRT-PCR). We
investigated the correlation between the relative expres-
sion of miR-126 and clinicopathological parameters to
evaluate its clinical significance. Additionally, we assessed
the influence of miR-126 expression on the biochemical
recurrence (BCR) of PCa patients.
Materials and methods
Patients and tissue samples
The study was approved by the Research Ethics Com-
mittee of Xi’an hong hui hospital and Xi’an electricity
power Center Hospital. Written informed consent was
obtained from all of the patients. All specimens were
handled and made anonymous according to the ethical
and legal standards.
One hundred and twenty-eight primary PCa and cor-
responding noncancerous prostate tissue samples from
the same specimens (n = 128) were collected from Xi’an
hong hui hospital and Xi’an electricity power Center
Hospital, from 1996 to 2008. None of the patients re-
ceived androgen deprivation treatment, chemotherapy,
or radiation therapy prior to radical prostatectomy. All
128 patients with PCa received radical prostatectomy.
The complete records of the cases pre- and post-operation,
and samples of the primary tissue, had been preserved.
The following clinicopathological parameters, including
preoperative PSA, Gleason score, pathological stage, lymph
node status, angiolymphatic invasion, margin status, and
biochemical relapse, were recorded. The clinicopathologi-
cal information of the patients is shown in Table 1.
All 128 patients with PCa were given a follow-up exam
ranging from three to ten years. All the patients who
died from diseases other than PCa or from unexpected
events were excluded from the case collection. For the
analysis of biochemical recurrence-free survival, the date
Table 1 Correlation of miR-126 expression with clinicopathological features of PCa patients
Clinicopathological features Cases No (n, %) miR-126 expression status P
Low (n, %) High (n, %)
Age
<70 70 (54.69) 39 (55.71) 31 (44.29) NS
≥70 58 (45.31) 29 (50.00) 29 (50.00)
Preoperative PSA
<4 ng/mL 3 (2.34) 0 (0) 3 (100.00) 0.003
4-10 ng/mL 35 (27.34) 7 (20.00) 28 (80.00)
>10 ng/mL 90 (70.31) 61 (67.77) 29 (32.23)
Gleason score
4-6 62 (48.44) 31 (50.00) 31 (50.00) NS
7 30 (23.44) 19 (63.33) 11 (36.67)
8-10 36 (28.13) 18 (50.00) 18 (50.00)
Pathological stage
T1 72 (56.25) 22 (30.56) 50 (69.44) 0.001
T2/T3 56 (43.75) 46 (82.14) 10 (17.86)
Lymph node metastasis
Negative 106 (82.81) 47 (44.34) 59 (55.66) 0.006
Positive 22 (17.19) 21 (95.45) 1 (4.55)
Angiolymphatic invasion
Negative 110 (85.94) 50 (45.45) 60 (54.55) 0.001
Positive 18 (14.06) 18 (100.00) 0 (0)
Surgical margin status
Negative 108 (84.38) 56 (51.85) 52 (48.15) NS
Positive 20 (15.62) 12 (60.00) 8 (40.00)
Note: ‘NS’ refers to the difference without statistic significance.
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the follow-up period. The endpoint was the time to bio-
chemical relapse which was defined as the period be-
tween surgical treatment and the measurement of two
successive values of serum PSA level ≥ 0.2 ng/ml.
qRT-PCR
RNA was extracted from fresh tissues of patients with PCa
using Trizol Reagent (Invitrogen, USA) according to the
manufacturer’s protocol. One microgram of total RNA
was reverse-transcribed using SuperScrip III (Invitrogen,
USA). After cDNA was synthesized with a miRNA-specific
stem-loop primer, the quantitative PCR was performed




GT-3′. Real-time PCR was performed using an Applied
Biosystems 7500 real-time PCR system using 1 μl reverse
transcriptase samples in a 20 μl final reaction mixture. 1X
TaqMan Universal PCR master mix (Takara, Japan) was
used for general PCR. RNU6B was used as an internalcontrol. Relative quantification of target miRNA expres-
sion was evaluated using the comparative cycle threshold
(CT) method. Each sample was examined in triplicate and
the amounts of the PCR products produced were nonneo-
plasticized to RNU6B.
Statistical analysis
Statistical analysis was performed using the software of
SPSS version12.0 for Windows (SPSS Inc, IL, USA). Con-
tinuous variables were expressed as mean ± S.D. Fisher’s
exact test and Pearson χ2 test were respectively used to
analyze 2 × 2 tables and non-2 × 2 tables. Kaplan-Meier
and Cox Regression methods were used for the question
of survival analysis. Differences were considered statisti-
cally significant when p was less than 0.05.
Results
Downregulation of miR-126 in PCa tissues
The expression levels of miR-126 were detected and ana-
lyzed in 128 pairs of PCa and adjacent non-cancerous
prostate tissues by qRT-PCR analysis. The results showed
that miR-126 expression level was significantly lower in
Figure 2 Biochemical recurrence (BCR)-free survival curves for
two groups defined by low and high expression of miR-126 in
patients with PCa. The patients with low miR-126 expression had
significantly shorter BCR-free survival after radical prostatectomy than
patients with high miR-126 expression did (P < 0.001).
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prostate tissues (1.05 ± 0.63 vs. 2.92 ± 0.98, P < 0.001,
Figure 1). Moreover, the median of miR-126 expression
levels in all PCa tissues was 1.02. Thus, the miR-126 ex-
pression levels were further analyzed by classifying as
low (n = 68, based on a relative expression level less than
1.02) and as high (n = 60, based on a relative expression
level greater than 1.02).
Downregulation of miR-126 correlates with aggressive
clinicopathological features of patients with PCa
Table 1 summarized the correlation between miR-126
expression and clinicopathological features of patients
with PCa. Our data showed that low miR-126 expression
was significantly correlated with aggressive clinical patho-
logical features, including advanced pathological stage
(P = 0.001), positive lymph node metastasis (P = 0.006),
high preoperative PSA (P = 0.003) and positive angiolym-
phatic invasion (P = 0.001). However, the expression status
of miR-126 was not associated with patients’ age, Gleason
score, and surgical margin status.
Prognostic value of miR-126 expression in PCa patients
To evaluate the possible prognostic value of miR-126,
we performed BCR-free survival analysis for all 128 PCa
patients undergoing radical prostatectomy. As shown in
Figure 2, Kaplan-Meier curves were plotted between
high or low miR-126 expression and BCR-free survival.
Notably, patients with low miR-126 expression had sig-
nificantly shorter BCR-free survival after radical prosta-
tectomy than patients with high miR-126 expression didFigure 1 microRNA-126 (miR-126) expression in 128 prostate
cancer (PCa) tissues and matched non-cancerous prostate
tissues normalized to RNU6B detected by quantitative
reverse-transcription PCR (qRT-PCR) assay. The expression levels
of miR-126 were detected and analyzed in 128 pairs of PCa and
adjacent non-cancerous prostate tissues by qRT-PCR analysis. The
results showed that miR-126 expression level was significantly lower
in PCa tissues compared to that in adjacent non-cancerous prostate
tissues (1.05 ± 0.63 vs. 2.92 ± 0.98, P < 0.001).(P < 0.001; Figure 2). In addition, the univariate analysis
with Cox proportional hazards model found that miR-126
expression status (P < 0.001), pathological stage (P < 0.001),
lymph node metastasis status (P = 0.002), and positive
angiolymphatic invasion (P < 0.001) were significantly as-
sociated with BCR-free survival, while patients’ age, pre-
operative PSA, Gleason score, and surgical margin status
were not significant factors (all P > 0.05, Table 2).
Furthermore, the Cox multivariate analysis demon-
strated the value of miR-126 expression, and otherTable 2 Univariate survival analysis of biochemical
recurrence (BCR)-free survival in 128 patients with PCa
Variables BCR-free survival
Exp (B) 95% CI P
Age (<70 vs. ≥70) 2.68 0.17–5.03 NS
Preoperative PSA (<10 ng/mL vs.
≥10 ng/mL)
2.34 0.11–4.48 NS
Gleason score (4–6 vs. 7–10) 2.26 0.10–4.32 NS










miR-126 expression (High vs. Low) 5.68 1.19–11.33 <0.001
Note: ‘NS’ refers to the difference without statistic significance.
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vival of patients with PCa. As shown in Table 3, miR-126
expression status (P = 0.01), pathological stage (P = 0.001),
lymph node metastasis status (P = 0.03), and positive an-
giolymphatic invasion (P = 0.001) were all independent
prognostic factors for predicting BCR-free survival of pa-
tients with PCa.
Discussion
Although patients with localized PCa receiving radical
prostatectomy have experienced long-term survival, the
BCR, which is generally considered as the earliest indica-
tor of recurrent disease, occurs in nearly half of patients
following surgery on long-term follow-up [21]. Thus, it
is very important to detect the early risk of BCR in order
to improve the prognosis of patients with PCa. Hua
et al. [22] identified GOLPH3 as an important prog-
nostic factor for patients with PCa; Jonsson et al. [23]
demonstrated that high RBM3 expression in PCa may
independently predict a reduced risk of BCR and disease
progression. In this study, we detected the aberrant ex-
pression of miR-126 in a large PCa cohort. As the results,
we firstly found that the expression level of miR-126 in
PCa tissues was significantly lower than that in adjacent
non-cancerous prostate tissues. In addition, the downreg-
ulation of miR-126 was significantly associated with ag-
gressive clinicopathological features, including advanced
pathological stage, positive lymph node metastasis, high
preoperative PSA and positive angiolymphatic invasion,
but not with patients’ age, Gleason score, and surgical
margin status. Moreover, we proved that miR-126 expres-
sion was significantly associated with BCR-free survival of
patients with PCa. More importantly, the multivariate
analyses showed that loss of miR-126 expression was an
independent predictor of shorter BCR-free survival in pa-
tients with PCa. These findings suggest that miR-126 may
play crucial roles in the pathogenesis and aggressiveness
of PCa, and miR-126 downregulation especially may be
correlated with the unfavorable prognosis in PCa. To our
knowledge, this is the first study to investigate the associ-
ation between miR-126 and PCa.
miR-126, an endothelial-specific miRNA, is generated by
EGFL7 pre-mRNA splicing [24]. Its expression is regulatedTable 3 Multivariate survival analysis of biochemical
recurrence (BCR)-free survival in 128 patients with PCa
Variables BCR-free survival
Exp (B) 95% CI P
Pathological stage 4.11 1.02–8.08 0.001
Lymph node metastasis 3.13 0.81–4.20 0.03
Angiolymphatic invasion 4.62 1.13–9.09 0.001
miR-126 expression 3.68 0.99–6.83 0.01
Note: ‘NS’ refers to the difference without statistic significance.by of EGFL7 gene promoter [24]. Since an intronic
miRNA tends to be co-expressed with its host gene, miR-
126 and its host gene, EGFL7, are both downregulated by
DNA methylation, with restoration of expression levels by
epigenetic treatment [25]. Functionally, miR-126 governs
angiogenesis and vascular integrity [26]. miR-126 down-
regulation in the endothelial cells leads to the activation
of vascular cell adhesion molecule-1 and subsequently
triggers adhesion of leukocytes to the injured vessels to
induce inflammatory changes. During atherosclerosis-
induced apoptosis in the endothelium, miR-126 is released
into the apoptotic bodies and confers a counteraction of
apoptosis and recruitment of vascular progenitor cells to
the site of injury [27,28]. Since these processes are impli-
cated into the developing cancer stroma, miR-126 may
play a role in carcinogenesis and cancer progression. A
number of studies have demonstrated that miR-126 acts as
a tumor suppressor gene in various human cancers. The
downregulation of miR-126 has been observed in adult T-
cell leukemia [29], oral squamous cell carcinoma [19,30],
nonsmall cell lung cancer [16], breast cancer [17], cervical
cancer [31], hepatocellular carcinoma [32], colorectal can-
cer [18], and gastric cancer [33]. In line with these previ-
ous studies, our data here also showed the loss of miR-126
expression in human PCa tissues, suggesting that the aber-
rant expression of miR-126 may be involved in the car-
cinogenesis of prostate. Regarding the clinical significance
of miR-126, accumulating studies have indicated that the
downregulation of miR-126 may be associated with ad-
vanced tumor progression and unfavorable outcome in
cancer patients, which is also similar with our results in
the current study. Therefore, it is conceivable that miR-
126 may play an important role in tumor metastasis and
tumor recurrence of PCa.
The limitation of the current study is that we did not
investigate the mechanism of miR-126 acting on PCa. In
breast cancer, the role of miR-126 in tumor metastasis
may be related to the negative regulation of insulin re-
ceptor substrate-1 expression and it inhibits endothelial
cell recruitment and angiogenesis through the negative
regulation of IGFBP2/IGF1/IGF1R and GAS6/ MERTK
signaling pathways [17]. In non-small cell lung cancer,
miR-126 blocked the activity of Crk leading to suppress-
ing the tumor cell metastasis [16]. In gastric cancer tis-
sues, miR-126 can also directly inhibit VEGF signaling
pathways, including expression of PIK3R2 and p85-b,
thereby playing a role in anti-angiogenesis and inhibition
of vascular integrity [33]. In colon cancer, miR-126 sup-
presses cancer cell proliferation and invasion via inhibiting
RhoA/ROCK signaling pathway [18]. In cervical cancer,
the repression of miR-126 may facilitate tumor angiogen-
esis and invasion growth by upregulating a proangiogenic
gene adrenomedullin [31]. However, the precise molecular
mechanisms behind the aberrant expression of miR-126
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problem may be essential and required.
In conclusion, our data suggest for the first time that
loss of miR-126 may play a positive role in the malignant
progression of PCa. More importantly, the downregula-
tion of miR-126 may serve as an independent predictor
of BCR-free survival of patients with PCa.
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